Translating Microbiome R&D into Improved Healthcare Outcomes & Commercial Potential
While Infant Bacterial Therapeutics pushes towards pharmaceutical registration, MRM Health pioneers live microbial consortium therapies for IBD and Microbiotica accelerates into the clinic with assets for advanced melanoma and UC. The microbiome biotech pipeline is overflowing with compelling data, increasingly validating the transformative potential of microbiome-based therapies across diverse disease areas.
With the first LBP approvals on the horizon, but financial pressures threatening to slow progress, the 9th Microbiome Movement Summit Europe returns to Barcelona this January as the essential industry hub for R&D and business leaders determined to push the field forward.
Explore the latest advances in microbiome science, where innovative biotechs are uncovering new microbial targets, deciphering mechanisms of action and harnessing state-of-the-art analytical tools to uncover the microbiome’s role in disease. Engage with investors and C-level leaders as we strategise how to bring big pharma back into the fold of emerging microbial modalities.
Join a community of 100+ industry leaders to drive the future of microbial pipeline innovation in a sector bursting with therapeutic potential!
What's New for 2025?
Get Closer to Clinical Readouts
Hear first-hand from industry leaders including Seres Therapeutics, MRM Health, and EXELIOM Biosciences as they reveal key insights into advancing LBP candidates and share new clinical data.
Navigate Paths to Clinical Readiness
Discover how Microbiotica has tackled regulatory hurdles head-on, ensuring you’re prepared to anticipate CMC challenges and secure the funding needed to reach Phase I. Learn from BioGaia Pharma and Luca Bio on innovative business models where consumer-stage candidates fast track therapeutics programmes back into drug development, offering a new way to navigate financial pressures while advancing R&D.
Explore Cutting-Edge Analytics & Emerging Modalities
From Kanvas Biosciences’ use of spatial biology to optimise consortia selection, to PharmaBiome’s big data-driven predictions of in-human responses, analytical innovation is moving fast. Be inspired by Prokarium’s programmable bacteria and Intrinsic Medicine’s research to target the gut-brain axis, to gain crucial therapeutic landscape insights to sharpen your competitive edge.
Our World-Class Speaker Faculty Includes:
Don't Just Take Our Word For It! Our Attendees Say:
Proud to Partner With:
Lead Partner
Expertise Partners
Exhibition Partner
Events in the Series:
